- Home
- EVGO vs TSHA Comparison
EVGO vs TSHA Comparison
Compare EVGO & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- TSHA
- Stock Information
- Founded
- EVGO 2010
- TSHA 2019
- Country
- EVGO United States
- TSHA United States
- Employees
- EVGO N/A
- TSHA N/A
- Industry
- EVGO Other Specialty Stores
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- TSHA Health Care
- Exchange
- EVGO Nasdaq
- TSHA Nasdaq
- Market Cap
- EVGO 376.5M
- TSHA 397.8M
- IPO Year
- EVGO N/A
- TSHA 2020
- Fundamental
- Price
- EVGO $3.95
- TSHA $2.71
- Analyst Decision
- EVGO Strong Buy
- TSHA Strong Buy
- Analyst Count
- EVGO 9
- TSHA 7
- Target Price
- EVGO $6.25
- TSHA $7.00
- AVG Volume (30 Days)
- EVGO 6.2M
- TSHA 5.2M
- Earning Date
- EVGO 05-06-2025
- TSHA 05-15-2025
- Dividend Yield
- EVGO N/A
- TSHA N/A
- EPS Growth
- EVGO N/A
- TSHA N/A
- EPS
- EVGO N/A
- TSHA N/A
- Revenue
- EVGO $276,954,000.00
- TSHA $7,224,000.00
- Revenue This Year
- EVGO $41.32
- TSHA N/A
- Revenue Next Year
- EVGO $33.95
- TSHA N/A
- P/E Ratio
- EVGO N/A
- TSHA N/A
- Revenue Growth
- EVGO 45.15
- TSHA N/A
- 52 Week Low
- EVGO $1.92
- TSHA $1.05
- 52 Week High
- EVGO $9.07
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EVGO 63.49
- TSHA 60.38
- Support Level
- EVGO $3.33
- TSHA $2.44
- Resistance Level
- EVGO $4.50
- TSHA $2.95
- Average True Range (ATR)
- EVGO 0.31
- TSHA 0.25
- MACD
- EVGO -0.01
- TSHA -0.02
- Stochastic Oscillator
- EVGO 52.99
- TSHA 51.60
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.